Literature DB >> 7836734

Angiotensin II formation by an alternative pathway during exercise in humans.

S Miura1, M Ideishi, T Sakai, M Motoyama, A Kinoshita, M Sasaguri, H Tanaka, M Shindo, K Arakawa.   

Abstract

OBJECTIVE: We postulated a 'kinin-tensin system' in which angiotensin II (Ang II) is cleaved by one or more serine protease independent of renin or angiotensin converting enzyme (ACE). The aim was to determine whether this alternative Ang II-forming pathway by serine proteases participates in the rise in plasma levels of Ang II during exercise in humans. DESIGN AND METHODS: The study consisted of two double-blind crossover experiments. in experiment 1 six healthy volunteers who had been taking either placebo (group P) or the ACE inhibitor captopril (150 mg/day for 3 days; group C) performed a cycle ergometer graded exercise test at four different exercise intensities: stage 1, half of the intensity at the blood lactate threshold (WLT); stage 2, the intensity at WLT; stage 3, the intensity at 4 mmol/l blood lactate; and stage 4, an intensity between stage 3 and maximum intensity. In experiment 2 the same volunteers took captopril (150 mg/day for 3 days) and performed exercise at an intensity corresponding to 90% of the 4 mmol/l blood lactate intensity for 30 min during intravenous drip injection of a serine protease inhibitor, nafamostat [NAF; 0.2 mg/kg per h; NAF(+) group] or saline [NAF(-) group].
RESULTS: In experiment 1 plasma Ang II levels increased from at rest to after exercise in both groups P and C. Although there was a significant treatment effect, captopril did not significantly alter the exercise-induced changes in Ang II level. In experiment 2 the increase in Ang II level after 30 min exercise in the NAF(+) group was significantly lower than in the NAF(-) group.
CONCLUSIONS: These results suggest the presence of an alternative Ang II-forming pathway independent of ACE, and that one or more NAF-sensitive serine protease is responsible, at least partly, for generating Ang II during exercise.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7836734

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  An exaggerated blood pressure response to exercise is associated with nitric oxide bioavailability and inflammatory markers in normotensive females.

Authors:  Ryoma Michishita; Masanori Ohta; Masaharu Ikeda; Ying Jiang; Hiroshi Yamato
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

2.  Hypertension during Weight Lifting Reduces Flow-Mediated Dilation in Nonathletes.

Authors:  Cullen E Buchanan; Andrew O Kadlec; Anne Z Hoch; David D Gutterman; Matthew J Durand
Journal:  Med Sci Sports Exerc       Date:  2017-04       Impact factor: 5.411

Review 3.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

4.  Endogenous production of angiotensin II modulates rat proximal tubule transport.

Authors:  A Quan; M Baum
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

5.  Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation.

Authors:  Y Hojo; U Ikeda; T Katsuki; O Mizuno; H Fujikawa; K Shimada
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

6.  Serum activity of Angiotensin converting enzyme and blood pressure response to acute dynamic exercise.

Authors:  Emina Nakas-Ićindić; Adnan Hadzimuratović; Jasminko Huskić; Almira Hadzović; Asija Zaciragić; Nesina Avdagić
Journal:  Bosn J Basic Med Sci       Date:  2004-10       Impact factor: 3.363

7.  The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.

Authors:  David Woods; Julie Sanders; Alun Jones; Emma Hawe; Peter Gohlke; Steve E Humphries; John Payne; Hugh Montgomery
Journal:  Eur J Appl Physiol       Date:  2003-11-01       Impact factor: 3.078

Review 8.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

Review 9.  The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 4.271

10.  Exercise intensity modulates capillary perfusion in correspondence with ACE I/D modulated serum angiotensin II levels.

Authors:  Sander van Ginkel; Arnold de Haan; Jorn Woerdeman; Luc Vanhees; Erik Serné; Jos de Koning; Martin Flück
Journal:  Appl Transl Genom       Date:  2015-03-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.